Baidu
map

CLIN CANCER RES:工程化分泌检查点抑制剂的CAR-T细胞免疫治疗疗效增强

2017-11-24 MedSci MedSci原创

尽管CAR-T细胞疗法在治疗血液肿瘤方面有一定的治疗效果,但是对实体肿瘤的治疗一直无法达到满意的疗效,其中的部分原因是抑制性肿瘤微环境的作用。CLIN CANCER RES近期发表了一篇文章,作者工程化建立了分泌靶向PD-1检查点抑制剂(CPI)的CAR-T细胞(CAR.αPD1-T)并评估其在人肺癌异种移植模型中的疗效。

尽管CAR-T细胞疗法在治疗血液肿瘤方面有一定的治疗效果,但是对实体肿瘤的治疗一直无法达到满意的疗效,其中的部分原因是抑制性肿瘤微环境的作用。CLIN CANCER RES近期发表了一篇文章,作者工程化建立了分泌靶向PD-1检查点抑制剂(CPI)的CAR-T细胞(CAR.αPD1-T)并评估其在人肺癌异种移植模型中的疗效。

作者在体外实验中评估CAR.αPD1-T细胞功能及扩增能力。抗原特异性刺激后测量IFNγ和细胞增殖情况。使用异种移植模型评估CAR.αPD1-T,CAR-T和CAR-T联合抗PD-1抗体的抗肿瘤效果。通过分析肿瘤浸润淋巴细胞(TIL)浸润和功能分析其机制。研究结果表明,CAR.αPD1-T分泌的人抗PD-1 CPIs可以有效结合PD-1并逆转PD-1/PD-L1介导的T细胞功能抑制作用。持续分泌的抗PD-1导致的PD-1信号阻断可以衰减抑制性T细胞信号,增强T细胞浸润和效应T细胞功能。在异种移植模型中,抗PD-1分泌可以增强CAR-T细胞抗肿瘤活性,延长总生存。

文章最后认为,通过抗PD-1分泌,CAR.αPD1-T功能及扩增能力更强,在清除肿瘤方面的能力优于亲代CAR-T细胞。该研究提供了一种重要的增强CAR-T细胞能力以达到更好的抗肿瘤免疫的方法,特别是在治疗实体肿瘤方面。

原始出处:
Si Li,Natnaree Siriwon,et al.Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.CLIN CANCER RES.November 2017 doi:10.1158/1078-0432.CCR-17-0867

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1682382, encodeId=531d168238202, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Fri Dec 01 18:38:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851579, encodeId=3df518515e9c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 04 23:38:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736962, encodeId=64561e369629e, content=<a href='/topic/show?id=01b5e7794fb' target=_blank style='color:#2F92EE;'>#细胞免疫治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77794, encryptionId=01b5e7794fb, topicName=细胞免疫治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c76d34226630, createdName=ms3117646317107274, createdTime=Tue May 29 09:38:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781195, encodeId=40441e81195bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 11 19:38:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407591, encodeId=8b32140e591af, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Sun Nov 26 00:38:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263917, encodeId=7c3c26391e4e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/26/c8b491d4a115552789c06a0aff6346a7.jpg, createdBy=f1941967364, createdName=1e14ffd0m25(暂无匿称), createdTime=Fri Nov 24 10:04:30 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2017-12-01 gwc392
  2. [GetPortalCommentsPageByObjectIdResponse(id=1682382, encodeId=531d168238202, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Fri Dec 01 18:38:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851579, encodeId=3df518515e9c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 04 23:38:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736962, encodeId=64561e369629e, content=<a href='/topic/show?id=01b5e7794fb' target=_blank style='color:#2F92EE;'>#细胞免疫治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77794, encryptionId=01b5e7794fb, topicName=细胞免疫治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c76d34226630, createdName=ms3117646317107274, createdTime=Tue May 29 09:38:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781195, encodeId=40441e81195bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 11 19:38:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407591, encodeId=8b32140e591af, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Sun Nov 26 00:38:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263917, encodeId=7c3c26391e4e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/26/c8b491d4a115552789c06a0aff6346a7.jpg, createdBy=f1941967364, createdName=1e14ffd0m25(暂无匿称), createdTime=Fri Nov 24 10:04:30 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2018-03-04 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1682382, encodeId=531d168238202, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Fri Dec 01 18:38:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851579, encodeId=3df518515e9c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 04 23:38:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736962, encodeId=64561e369629e, content=<a href='/topic/show?id=01b5e7794fb' target=_blank style='color:#2F92EE;'>#细胞免疫治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77794, encryptionId=01b5e7794fb, topicName=细胞免疫治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c76d34226630, createdName=ms3117646317107274, createdTime=Tue May 29 09:38:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781195, encodeId=40441e81195bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 11 19:38:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407591, encodeId=8b32140e591af, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Sun Nov 26 00:38:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263917, encodeId=7c3c26391e4e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/26/c8b491d4a115552789c06a0aff6346a7.jpg, createdBy=f1941967364, createdName=1e14ffd0m25(暂无匿称), createdTime=Fri Nov 24 10:04:30 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1682382, encodeId=531d168238202, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Fri Dec 01 18:38:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851579, encodeId=3df518515e9c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 04 23:38:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736962, encodeId=64561e369629e, content=<a href='/topic/show?id=01b5e7794fb' target=_blank style='color:#2F92EE;'>#细胞免疫治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77794, encryptionId=01b5e7794fb, topicName=细胞免疫治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c76d34226630, createdName=ms3117646317107274, createdTime=Tue May 29 09:38:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781195, encodeId=40441e81195bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 11 19:38:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407591, encodeId=8b32140e591af, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Sun Nov 26 00:38:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263917, encodeId=7c3c26391e4e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/26/c8b491d4a115552789c06a0aff6346a7.jpg, createdBy=f1941967364, createdName=1e14ffd0m25(暂无匿称), createdTime=Fri Nov 24 10:04:30 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2018-09-11 仁者大医
  5. [GetPortalCommentsPageByObjectIdResponse(id=1682382, encodeId=531d168238202, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Fri Dec 01 18:38:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851579, encodeId=3df518515e9c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 04 23:38:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736962, encodeId=64561e369629e, content=<a href='/topic/show?id=01b5e7794fb' target=_blank style='color:#2F92EE;'>#细胞免疫治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77794, encryptionId=01b5e7794fb, topicName=细胞免疫治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c76d34226630, createdName=ms3117646317107274, createdTime=Tue May 29 09:38:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781195, encodeId=40441e81195bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 11 19:38:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407591, encodeId=8b32140e591af, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Sun Nov 26 00:38:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263917, encodeId=7c3c26391e4e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/26/c8b491d4a115552789c06a0aff6346a7.jpg, createdBy=f1941967364, createdName=1e14ffd0m25(暂无匿称), createdTime=Fri Nov 24 10:04:30 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1682382, encodeId=531d168238202, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Fri Dec 01 18:38:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851579, encodeId=3df518515e9c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 04 23:38:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736962, encodeId=64561e369629e, content=<a href='/topic/show?id=01b5e7794fb' target=_blank style='color:#2F92EE;'>#细胞免疫治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77794, encryptionId=01b5e7794fb, topicName=细胞免疫治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c76d34226630, createdName=ms3117646317107274, createdTime=Tue May 29 09:38:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781195, encodeId=40441e81195bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 11 19:38:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407591, encodeId=8b32140e591af, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Sun Nov 26 00:38:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263917, encodeId=7c3c26391e4e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/26/c8b491d4a115552789c06a0aff6346a7.jpg, createdBy=f1941967364, createdName=1e14ffd0m25(暂无匿称), createdTime=Fri Nov 24 10:04:30 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2017-11-24 1e14ffd0m25(暂无匿称)

    学习了

    0

相关资讯

全球CAR-T临床研究项目盘点:4年新增项目数量翻4.5倍

我国的CAR-T研究虽然起步不算早,但从2013年增长迅猛。目前,我国的临床研究项目位于全球第二,仅次于美国。

Cancer Discov:这项新发现有望减少CAR-T疗法副作用

尽管癌症研究者们因最近诺华CAR-T疗法Kymriah获得FDA批准而感到兴奋,但是对于其副作用的担忧依然困扰着学界。在诺华的这一疗法以及其它类似疗法的临床试验中,一些患者发生了称为细胞因子释放综合征的危险的免疫反应,还有一部分患者发生神经毒性。这些副作用严重时可能危及生命。

天津血液肿瘤高峰论坛:梁爱斌教授分享CAR-T研发的经验和思考

刚刚入选2017年国家百千万人才工程名单、被授予“有突出贡献中青年专家”荣誉称号的梁爱斌教授,是国内最早开展CAR-T研究的专家之一。

Blood:靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。

Lymphodepletion化疗联合CD19靶向嵌合抗原受体修饰的T(CAR-T)细胞是对难治性或复发性B细胞恶性肿瘤的新型疗法。然而,针对这种疗法的感染性并发症尚未有过系统的研究。

全球首条全自动、全封闭的CAR-T细胞CMC生产线首次亮相国内

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li

CAR-T市场呈指数增长,人类进入新的医学创新前沿

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; f

Baidu
map
Baidu
map
Baidu
map